Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

S Marr

Showing results (131-140 of 144) with videos related to

Pageof 15
Sort By:
Bioorganic & Medicinal Chemistry Letters|May 6, 2008
Synthesis and structure based optimization of novel Akt inhibitorsBlaise Lippa, Gonghua Pan, Matthew Corbett, et al.
British Journal of Haematology|July 22, 2014
A novel canine model of immune thrombocytopenia: has immune thrombocytopenia (ITP) gone to the dogs?Dana N LeVine, Adam J Birkenheuer, Marjory B Brooks, et al.
JCO Precision Oncology|July 16, 2024
Palbociclib in Patients With Soft Tissue Sarcoma With <i>CDK4</i> Amplifications: Results From the Targeted Agent and Profiling Utilization Registry StudyScott Schuetze, Michael Rothe, Pam K Mangat, et al.
Clinical Proteomics|January 9, 2019
Identification of <i>Cytauxzoon felis</i> antigens via protein microarray and assessment of expression library immunization against cytauxzoonosisMegan E Schreeg, Henry S Marr, Jaime L Tarigo, et al.
JCO Precision Oncology|January 20, 2022
Palbociclib in Patients With Non-Small-Cell Lung Cancer With <i>CDKN2A</i> Alterations: Results From the Targeted Agent and Profiling Utilization Registry StudyEugene R Ahn, Pam K Mangat, Elizabeth Garrett-Mayer, et al.
Journal of Medicinal Chemistry|November 13, 2013
Discovery and characterization of a novel dihydroisoxazole class of α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptor potentiatorsNandini C Patel, Jacob Schwarz, Xinjun J Hou, et al.
Journal of Medicinal Chemistry|June 10, 2011
Use of structure-based design to discover a potent, selective, in vivo active phosphodiesterase 10A inhibitor lead series for the treatment of schizophreniaChristopher J Helal, Zhijun Kang, Xinjun Hou, et al.
JCO Precision Oncology|December 1, 2023
Nivolumab Plus Ipilimumab in Patients With Solid Tumors With <i>ATM</i> Mutations: Results From the Targeted Agent and Profiling Utilization Registry (TAPUR) StudyNitin Rohatgi, Michael Rothe, Pam K Mangat, et al.
Journal of Medicinal Chemistry|September 2, 2005
Theoretical and experimental design of atypical kinase inhibitors: application to p38 MAP kinaseKim F McClure, Yuriy A Abramov, Ellen R Laird, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 10, 2023
Pembrolizumab in Patients With Tumors With High Tumor Mutational Burden: Results From the Targeted Agent and Profiling Utilization Registry StudyHerbert L Duvivier, Michael Rothe, Pam K Mangat, et al.
Pageof 15

Showing results (131-140 of 144) with videos related to

Sort By:
Pageof 15
Bioorganic & Medicinal Chemistry Letters|May 6, 2008
Synthesis and structure based optimization of novel Akt inhibitorsBlaise Lippa, Gonghua Pan, Matthew Corbett, et al.
British Journal of Haematology|July 22, 2014
A novel canine model of immune thrombocytopenia: has immune thrombocytopenia (ITP) gone to the dogs?Dana N LeVine, Adam J Birkenheuer, Marjory B Brooks, et al.
JCO Precision Oncology|July 16, 2024
Palbociclib in Patients With Soft Tissue Sarcoma With <i>CDK4</i> Amplifications: Results From the Targeted Agent and Profiling Utilization Registry StudyScott Schuetze, Michael Rothe, Pam K Mangat, et al.
Clinical Proteomics|January 9, 2019
Identification of <i>Cytauxzoon felis</i> antigens via protein microarray and assessment of expression library immunization against cytauxzoonosisMegan E Schreeg, Henry S Marr, Jaime L Tarigo, et al.
JCO Precision Oncology|January 20, 2022
Palbociclib in Patients With Non-Small-Cell Lung Cancer With <i>CDKN2A</i> Alterations: Results From the Targeted Agent and Profiling Utilization Registry StudyEugene R Ahn, Pam K Mangat, Elizabeth Garrett-Mayer, et al.
Journal of Medicinal Chemistry|November 13, 2013
Discovery and characterization of a novel dihydroisoxazole class of α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptor potentiatorsNandini C Patel, Jacob Schwarz, Xinjun J Hou, et al.
Journal of Medicinal Chemistry|June 10, 2011
Use of structure-based design to discover a potent, selective, in vivo active phosphodiesterase 10A inhibitor lead series for the treatment of schizophreniaChristopher J Helal, Zhijun Kang, Xinjun Hou, et al.
JCO Precision Oncology|December 1, 2023
Nivolumab Plus Ipilimumab in Patients With Solid Tumors With <i>ATM</i> Mutations: Results From the Targeted Agent and Profiling Utilization Registry (TAPUR) StudyNitin Rohatgi, Michael Rothe, Pam K Mangat, et al.
Journal of Medicinal Chemistry|September 2, 2005
Theoretical and experimental design of atypical kinase inhibitors: application to p38 MAP kinaseKim F McClure, Yuriy A Abramov, Ellen R Laird, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 10, 2023
Pembrolizumab in Patients With Tumors With High Tumor Mutational Burden: Results From the Targeted Agent and Profiling Utilization Registry StudyHerbert L Duvivier, Michael Rothe, Pam K Mangat, et al.
Pageof 15